Carolina Reduzzi
CancerPathologyOncologyCellGene expressionProspective cohort studyMetastatic breast cancerSingle-cell analysisMUC1Renal cell carcinomaMetastasisTumor progressionLiquid biopsyProgression-free survivalCancer researchBreast cancerCirculating tumor cellMedicineBiomarker (medicine)Biology
23Publications
6H-index
89Citations
Publications 22
Newest
#1Marco SilvestriH-Index: 3
#2Carolina ReduzziH-Index: 6
Last. Vera CappellettiH-Index: 21
view all 15 authors...
Circulating tumor microemboli (CTMs) are clusters of cancer cells detached from solid tumors, whose study can reveal mechanisms underlying metastatization. As they frequently comprise unknown fractions of leukocytes, the analysis of copy number alterations (CNAs) is challenging. To address this, we titrated known numbers of leukocytes into cancer cells (MDA-MB-453 and MDA-MB-36, displaying high and low DNA content, respectively) generating tumor fractions from 0–100%. After low-pass sequencing, ...
Source
#1Paolo D'AmicoH-Index: 6
#2Lorenzo GerratanaH-Index: 16
Last. Massimo CristofanilliH-Index: 78
view all 12 authors...
Source
#1Paolo D'AmicoH-Index: 6
#2Qiang ZhangH-Index: 18
Last. Massimo CristofanilliH-Index: 78
view all 12 authors...
Source
Source
#1Carolina ReduzziH-Index: 6
#2Youbin ZhangH-Index: 2
Last. Massimo CristofanilliH-Index: 78
view all 5 authors...
Source
#1Rokana TaftafH-Index: 3
#2Xia LiuH-Index: 16
Last. Huiping LiuH-Index: 28
view all 14 authors...
Source
In biliary tract cancer (BTC), tissue biopsies to guide treatment are rarely feasible, thus implementing liquid biopsy approaches to improve patient management represents a priority. So far, studies on circulating tumor cells (CTCs) in BTC are insufficient to promote their use in patient clinical management and are limited to EpCAM-enriched CTCs evaluated with the CellSearch. We applied a single-cell protocol allowing identification not only of epithelial CTCs (eCTCs), but also of nonconventiona...
2 CitationsSource
#1S. Di CosimoH-Index: 15
#2Marco SilvestriH-Index: 3
Last. M. G. DaidoneH-Index: 2
view all 9 authors...
Source
Circulating tumor cells (CTCs) are promising biomarkers for prognosis, therapeutic response prediction, and treatment monitoring in cancer patients. Despite its epithelial origin, renal cell carcinoma (RCC) shows low expression of epithelial markers hindering CTC-enrichment approaches exploiting epithelial cell surface proteins. In 21 blood samples serially collected from 10 patients with metastatic RCC entering the TARIBO trial, we overcame this limitation using the marker-independent Parsortix...
3 CitationsSource
#1Carolina ReduzziH-Index: 6
#2Lorenzo Gerratana (NU: Northwestern University)H-Index: 16
Last. Massimo Cristofanilli (NU: Northwestern University)H-Index: 78
view all 6 authors...
Background: The prognostic impact of circulating tumor cells (CTCs) in patients with breast cancer is well recognized. Nonetheless, by using the FDA-approved CellSearch™ platform, CTCs are detected only in a fraction of patients, both in early and metastatic breast cancer. Several investigators reported the presence of circulating cells expressing both epithelial and leukocyte markers (dual-positive cells, DPcells) in the blood of patients with breast cancer. In view of the fact that those cells...
Source
123
Close Researchers